Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Flu Antibody’s 'One-handed Grab' May… >
Flu Antibody’s 'One-handed Grab' May Boost Effort Toward Universal Vaccine, New Therapies

Published: September 17, 2012.
By Scripps Research Institute
http://www.scripps.edu

LA JOLLA, CA -- Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way. The antibody recognizes the crucial structure that flu viruses use to attach to host cells, even though previously this structure had been thought too small for an antibody to grab effectively. The immune protein manages to hit this precise spot by using just a small part of its target-grabbing apparatus. In so doing, it can neutralize a broad range of dangerous flu viruses.

"This highly focused binding to the receptor binding site using only a single loop on the antibody has never been seen before, and it's really fascinating; it gives us some good ideas about designs for vaccines and therapies," said Ian A. Wilson, the Hansen Professor of Structural Biology at Scripps Research. Wilson was senior investigator of the study along with Ramesh R. Bhatt of Sea Lane Biotechnologies. The report appears online ahead of print on September 16, 2012, in the journal Nature.

The Power of Large Numbers

Sea Lane Biotechnologies, advised by Richard Lerner, the Lita Annenberg Hazen Professor of Immunochemistry at Scripps Research, began by collecting bone marrow from patients who had been exposed to certain key strains of flu. Because the bone marrow is a "fossil record" of all the antibodies a person has ever made, those at Sea Lane felt confident that the antibodies they were looking for would be there. Sea Lane's efforts even went as far as to include advertised appeals on Craigslist for individuals who had certain strains of the flu. Using the internationally and locally collected bone marrow, Sea Lane generated a "comprehensive flu library" of billions of antibodies.

Sea Lane Biotechnologies scientists, led by Bhatt, isolated the unusual new antibody, which they dubbed C05, by screening this enormous library for antibodies that could bind to proteins from a variety of influenza A viruses—the most dangerous family of flu viruses.

C05 also protected cells in the lab dish from infection by these viruses. In mice, relatively low doses of C05 prevented infections despite influenza A exposures that would have been lethal. The antibody worked as a therapy, too, rescuing 100 percent of mice when administered up to three days after a flu infection had begun.

An Unusual Grip for a Tricky Target

Further tests revealed a curious property of C05. Almost uniquely among broadly neutralizing antibodies against influenza A, it specifically recognizes and blocks the part of the flu virus that mediates viral attachment to host cells. Known as the "receptor binding site" (RBS), this viral site is located on the heads of viral hemagglutinins, spiky structures of sugar and protein that coat the viral envelope.

The RBS is a key functional site on flu viruses and is relatively exposed to the immune system compared to other viral regions. It would be an ideal target for antibodies, except that it is quite small compared to an antibody's usual grip area.

An antibody binds targets using two arm-like structures, each of which has six protein fingers or loops. To get a good grip on the flu RBS with some or all these loops, a typical antibody has to grab not only the RBS, but also some of the surrounding structures in the head, which vary from one flu strain to another. Thus, an antibody that does get a firm grip on this region for one flu strain generally will lose that grip once the strain mutates. "This is why universal flu vaccine strategies in recent years have been focused more on the hemagglutinin stem than on the head," noted Damian C. Ekiert, formerly of Wilson's laboratory at Scripps Research and now of University of California, San Francisco. Ekiert was first author of the paper with Arun K. Kashyap of Sea Lane Biotechnologies.

Wilson's laboratory specializes in the use of X-ray crystallography and other techniques to determine precisely where and how such antibodies bind to their viral targets. Using these methods, his team found that C05 effectively avoids grabbing the hypervariable regions around the flu RBS. Instead it uses a single elongated protein loop to reach in and make a "one-handed"—or "one-fingered"—grab of the RBS itself. The antibody apparently works best when two of these active loops, one on each arm, grab two viral RBSs on separate hemagglutinins. "It looks like these antibodies need to cross-link two hemagglutinins to have maximum effect," said Wilson.

Potentially Useful

The RBS has such an important function that it does not change much from strain to strain—and thus C05 can neutralize a broad range of dangerous influenza A viruses, including H1, H2, H3, and H9 subtypes.

The fact that C05 can make such a precision grab suggests that it and perhaps even more potent antibodies could contribute to antibody-based therapies for severe influenza infections. A universal flu vaccine also might be significantly more effective if it could be designed to elicit such antibodies in people.

"If we can figure out how to induce this sort of antibody in a vaccine, we would have something that's very useful," said Lawrence Horowitz, CEO of Sea Lane Biotechnologies.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Antibodies 
1/10/11 
H1N1 Pandemic Points to Vaccine Strategy for Multiple Flu Strains
By University of Chicago Medical Center
Although the 2009 H1N1 influenza pandemic infected an estimated 60 million people and hospitalized more than 250,000 in the United States, it also brought one significant benefit—clues about how …
Ascs 
9/3/11 
Persistent Immunity: Wistar Researchers Find Signals That Preserve Anti-viral Antibodies
By The Wistar Institute
PHILADELPHIA – (September 1, 2011) – Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been …
Influenza 
8/10/12 
Scientists Describe Antibodies That Protect Against Large Variety of Flu Viruses
By Scripps Research Institute
LA JOLLA, CA – August 9, 2012 – A team led by scientists at The Scripps Research Institute and Crucell Vaccine Institute in the Netherlands describes three human antibodies …
Region 
1/9/14 
Engineered Anti-toxin Antibodies Improve Efficacy
By Journal of Clinical Investigation
The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent studies suggest that the …
Antibodies 
8/28/14 
Drug Shows Promise Against Sudan Strain of Ebola in Mice
By Albert Einstein College of Medicine
August 28, 2014 — (BRONX, NY) — Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus …
Variation 
10/23/13 
The Hitchhiker Antigen: Cause for Concern?
By Canadian Science Publishing (NRC Research Press)
Since antibodies first attained prominence as research reagents in modern biological science labs, researchers have been perplexed as to why one production lot can differ significantly from the next, …
H5n1 
8/25/14 
Key to Universal Flu Vaccine: Embrace the Unfamiliar
By Emory Health Sciences
Vaccine researchers have developed a strategy aimed at generating broadly cross-reactive antibodies against the influenza virus: embrace the unfamiliar. In recent years, researchers interested in a "universal flu …
Sudv 
8/27/14 
Potential Therapy for the Sudan Strain of Ebola Could Help Contain Some Future Outbreaks
By American Chemical Society
Ebola is a rare, but deadly disease that exists as five strains, none of which have approved therapies. One of the most lethal strains is the Sudan ebolavirus (SUDV). …
Potential 
7/8/10 
Antibody May Help Treat And Prevent Influenza Outbreaks
By Public Library of Science
Researchers have discovered a monoclonal antibody that is effective against "Avian" H5N1, seasonal H1N1 and the 2009 "Swine" H1N1 influenza. Scientists at Sea Lane Biotechnologies, LLC, in collaboration with …
Fi6 
7/28/11 
Humabs Discovers the First Antibody to Neutralize Both Group 1 And Group 2 Influenza a Viruses
By Financial Dynamics
BELLINZONA (Switzerland) – July 28, 2011 – A paper published today in the scientific research journal Science, describes a novel, proprietary monoclonal antibody (FI6) discovered in a collaboration between …
Viral 
4/5/13 
Highly Lethal Ebola Virus Has Diagnostic Achilles' Heel for Biothreat Detection, Scientists Say
By Texas Biomedical Research Institute
By screening a library of a billion llama antibodies on live Ebola viruses in the Texas Biomedical Research Institute's highest biocontainment laboratory, scientists in San Antonio have identified a …
Virus 
11/21/11 

Scripps Research Team Finds a Weak Spot on Deadly Ebolavirus
By Scripps Research Institute
Pad4 
5/22/13 
Enzyme-activating Antibodies Revealed as Marker for Most Severe Form of Rheumatoid Arthritis
By Johns Hopkins Medicine
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition